← Human Trials & Peer-Reviewed Studies
Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial.
Plain-language guide to PMID 41008575 (2025): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 41008575
- Journal
- Biomolecules
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Squitti R et al. (15 authors)
- DOI
- 10.3390/biom15091268
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Dysregulation contributes to Alzheimer's disease (AD) pathophysiology.
Individual biological responses may vary.
Who Took Part
PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.
ZINCAiD was a 24-week, randomized, double-blind, placebo-controlled phase II trial assessing zinc therapy in individuals with mild cognitive impairment (MCI) due to AD (EudraCT No.: 2019-000604-15; registered on 26 March 2020).
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Ceruloplasmin was measured at predefined intervals for safety monitoring, blinded to the investigators.
The primary cognitive endpoint was the Cognitive Composite 2 scale (CC2); secondary endpoints included MMSE and CDR-Sob.
What Was Measured
Topics PubMed links to this paper include Cognitive Dysfunction, Zinc, Ceruloplasmin, Cognition and Alzheimer Disease.
Author keywords: Alzheimer’s disease, clinical trial, copper, mild cognitive impairment and zinc therapy.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Biomolecules), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.